請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31474
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林仁混(Jen-Kun Lin) | |
dc.contributor.author | Tsai-Wen Chang | en |
dc.contributor.author | 張采文 | zh_TW |
dc.date.accessioned | 2021-06-13T03:13:29Z | - |
dc.date.available | 2013-10-05 | |
dc.date.copyright | 2011-10-05 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-29 | |
dc.identifier.citation | 1. White MF. 1997 The insulin signaling system and the IRS proteins. Diabetologia. 40(2):S2-S17.
2. Pessin JE, Saltiel AR. 2000 Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 106(2):165-169. 3. Bhattacharya S, Dey D, Roy SS. 2007 Molecular mechanism of insulin resistance. J. Biosci. 32(2):405–413. 4. Saltiel AR, Kahn CR. 2001 Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414(6865):799–806. 5. Loddick SA, Rothwell NJ. 1999 Mechanisms of tumor necrosis factor alpha action on neurodegeneration: interaction with insulin-like growth factor-1. Proc Natl Acad Sci U S A. 96(17):9449–9451. 6. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. 1996 IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 271(5249):665–668. 7. Yoshikawa T, Noguchi Y, Satoh S. 1999 Inhibition of IRS-1 phosphorylation and the alterations of GLUT4 in isolated adipocytes from cachectic tumor-bearing rats. Biochem Biophys Res Commun. 256(3):676–681. 8. Maezono K, Osman A, Patti ME, Cusi K, Pendergrass M, DeFronzo RA, Mandarino L. 1998 PI 3-kinase but not map kinase signaling is insulin resistant in obesity and niddm. Diabetes. 47(1):333A. 9. Kahn BB, Flier JS. 2000 Obesity and insulin resistance. J Clin Invest. 106(4):473–481. 10. Stumvoll M, Goldstein BJ, van Haeften TW. 2005 Type 2 diabetes: principles of phathogenesis and therapy. Lancet. 365(9467):1333-1346. 11. Zimmet PZ. 1999 Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 42(5):499–518. 12. Zimmet P, Alberti KG, Shaw J. 2001 Global and societal implications of the diabetes epidemic. Nature. 414(6865):782–787. 13. Boden G. 1997 Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 46(1):3-10. 14. Boden G, Chen X, Capulong E Mozzoli M. 2001 Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes. 50(4):810–816. 15. Kuhlmann J, Neumann-Haefelin C, Belz U, Kalisch J, Juretschke H P, Stein M, Kleinschmidt E, Kramer W, Herling AW. 2003 Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes. 52(1):138–144. 16. Shulman GI. 2000 Cellular mechanisms of insulin resistance. J Clin Invest. 106(2):171-176. 17. Peraldi P, Spiegelman B. 1998 TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem. 182(1-2):169-175. 18. Saltiel AR, Kahn CR. 2001 Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414(6865):799-806. 19. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH. 1997 Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 46(6):983–988. 20. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. 1999 Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 42(1):113–116. 21. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L. 1999 Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 48(8):1600–1606. 22. DeFronzo RA. 2004 Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 88(4):787–835. 23. Abdul-Ghani MA, DeFronzo RA. 2010 Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol. 2010:476279. 24. Perseghin G, Petersen K, Shulman GI. 2003 Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 27 Suppl 3:S6-S11. 25. llien D, Tanti JF, Heydrick SJ, Gautier N, Grémeaux T, Van Obberghen E, Le Marchand-Brustel Y. 1993 Differential effects of okadaic acid on insulin-stimulated glucose and amino acid uptake and phosphatidylinositol 3-kinase activity. J Biol Chem. 268(20):15246-15251. 26. Tanti JF, Grémeaux T, van Obberghen E, Le Marchand-Brustel Y. 1994 Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem. 269(8):6051-6057. 27. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular basis for insulin resistance. 1997 Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. 272(47):29911-29918. 28. Strack V, Hennige AM, Krützfeldt J, Bossenmaier B, Klein HH, Kellerer M, Lammers R, Häring HU. 2000 Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms beta2 and theta. Diabetologia. 43(4):443-449. 29. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF. 2001 Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest. 107(2):181-189. 30. Le Marchand-Brustel Y, Gual P, Grémeaux T, Gonzalez T, Barrès R, Tanti JF. 2003 Fatty acid-induced insulin resistance: role of insulin receptor substrate 1 serine phosphorylation in the retroregulation of insulin signalling. Biochem Soc Trans. 31(Pt 6):1152-1156. 31. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. 2002 Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 277(2):1531-1537. 32. Nishizuka Y. 1984 The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 308(5961):693-698. 33. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI. 1999 Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 48(6):1270-1274. 34. Bell KS, Schmitz-Peiffer C, Lim-Fraser M, Biden TJ, Cooney GJ, Kraegen EW. 2000 Acute reversal of lipid-induced muscle insulin resistance is associated with rapid alteration in PKC-theta localization. Am J Physiol Endocrinol Metab. 279(5):E1196-1201. 35. Chang JD, Xu Y, Raychowdhury MK, Ware JA. 1993 Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets. J Biol Chem. 268(19):14208-14214. 36. Jiang G, Dallas-Yang Q, Liu F, Moller DE, Zhang BB. 2003 Salicylic acid reverses PMA and TNF alpha-induced IRS1 serine 307 phosphorylation and insulin resistance in HEK 293 cells. J Biol Chem. 278(1):180–186. 37. Baldwin AS Jr. 1996 The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 14:649-683. 38. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI. 2001 Prevention of fatinduced insulin resistance by salicylate. J Clin Invest. 108(3):437-446. 39. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, Ye J. 2002 Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem. 277(50):48115-48121. 40. Lin X, O'Mahony A, Mu Y, Geleziunas R, Greene WC. 2000 Protein kinase C-theta participates in NF-kappa B activation induced by CD3-CD28 costimulation through selective activation of I kappa B kinase beta. Mol Cell Biol. 20(8):2933-2940. 41. Davis RJ. 2000 Signal transduction by the JNK group of MAP kinases. Cell. 103(2):239-252. 42. Aguirre V, Uchida T, Yenush L, Davis R, White MF. 2000 The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 275(12): 9047-9054. 43. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. 2002 A central role for JNK in obesity and insulin resistance. Nature. 420(6913):333-336. 44. Ragheb R, Shanab GM, Medhat AM, Seoudi DM, Adeli K, Fantus IG. 2009 Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun. 389(2):211-216. 45. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, Ye J. 2004 Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol. 18(8):2024-20234. 46. Long YC, Zierath JR. 2006 AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 116(7):1776-1783. 47. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. 2003 LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol. 13(22):2004-2008. 48. Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA. 2005. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem. 280(32):29060–29066. 49. Musi N, Goodyear LJ. 2003 AMP-activated protein kinase and muscle glucose uptake. Acta Physiol Scand. 178(4):337-345. 50. Ploug T, Galbo H, Vinten J, Jørgensen M, Richter EA. 1987 Kinetics of glucose transport in rat muscle: effects of insulin and contractions. Am J Physiol. 253(1 Pt 1):E12-E20. 51. Winder WW, Hardie DG. 1996 Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol. 270(2 Pt 1):E299-E304. 52. Fryer LG, Parbu-Patel A, Carling D. 2002. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 277(28):25226–25232. 53. Buhl ES, Jessen N, Schmitz O, Pedersen SB, Pedersen O, Holman GD, Lund S. 2001. Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D- ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber typespecific manner. Diabetes. 50(1): 12–17. 54. Somwar R, Perreault M, Kapur S, Taha C, Sweeney G, Ramlal T, Kim DY, Keen J, Côte CH, Klip A, Marette A. 2000 Activation of p38 mitogen-activated protein kinase and by insulin and constraction in rat skeletal muscle: potential role in the stimulation of glucose tranport. Diabetes. 49(11):1794-1800. 55. Xi X, Han J, Zhang JZ. 2001 Stimulation of glucose transport by AMP-activated protein kinase (AMPK) via activation of p38 mitogen-activated protein kinase (MAPK). J Biol Chem. 276(44):41029–41034. 56. Jakobsen SN, Hardie DG, Morrice N, Tornqvist, HE. 2001 5’-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem. 276(50): 46912–46916. 57. Schalch DS, Kipnis DM. 1965 Abnormalities in carbohydrate tolerance associated with elevated plasma nonesterified fatty acids. J Clin Invest. 44(12):2010-2020. 58. Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, 2004 Mandarino LJ. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes. 53(1):25-31. 59. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C. 2006 Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes. 55(8):2159-2170. 60. Bonnard C, Durand A, Peyrol S, Chanseaume E, Chauvin MA, Morio B, Vidal H, Rieusset J. 2008 Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest. 118(2):789-800. 61. Hulver MW, Berggren JR, Cortright RN, Dudek RW, Thompson RP, Pories WJ, MacDonald KG, Cline GW, Shulman GI, Dohm GL, Houmard JA. 2003 Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab. 284(4):E741-E747. 62. Winder WW, Wilson HA, Hardie DG, Rasmussen BB, Hutber CA, Call GB, Clayton RD, Conley LM, Yoon S, Zhou B. 1997. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J Appl Physiol. 82(1):219–225. 63. McKay DL, Blumberg JB. 2002 The role of tea in human health: an update, J Am Coll Nutr. 21(1):1–13. 64. Zaveri NT. 2006 Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 78(18):2073–2080. 65. Song EK, Hur H, Han MK. 2003 Epigallocatechin gallate prevents autoimmune diabetes induced by multiple low doses of streptozotocin in mice. Arch Pharm Res. 26(7):559-563. 66. Kao YH, Hiipakka RA, Liao S. 2000 Modulation of obesity by a green tea catechin. Am J Clin Nutr. 72(5):1232-1234. 67. Waltner-Law ME, Wang XL, Law BK, Hall RK, Nawano M, Granner DK. 2002 Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem. 277(38):34933-34940. 68. Ashida H, Furuyashiki T, Nagayasu H, Bessho H, Sakakibara H, Hashimoto T, Kanazawa K. 2004 Anti-obesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. Biofactors. 22(1-4):135-140. 69. Rizvi SI, Zaid MA, Anis R, Mishra N. 2005 Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes. Clin Exp Pharmacol Physiol. 32(1-2):70-75. 70. Kürbitz C, Heise D, Redmer T, Goumas F, Arlt A, Lemke J, Rimbach G, Kalthoff H, Trauzold A. 2011 Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. ncer Sci. 102(4):728-734. 71. Min-Hsiung Pan, Yi-Siou Chiou, Yin-Jen Wang, Chi-Tang Ho and Jen-Kun Lin 2010 Multistage carcinogenesis process as molecular targets in cancer chemoprevention by epicatechin-3-gallate. Food funct. DOI: 10.1039/c0fo00174k 72.Fujisawa S, Atsumi T, Ishihara M, Kadoma Y. 2004. Cytotoxicity, ROS-generation activity and radical scavenging activity of curcumin and related compounds. Anticancer Res. 24(2B):563–569. 73. Aggarwal BB, Kumar A, Bharati AC. 2003. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23(1A):363-398. 74. Grandjean-Laquerriere A, Gangloff SC, Le Naour R, Trentesaux C, Hornebeck W, Guenounou M. 2002 Relative contribution of NFkB and AP-1 in the modulation by curcumin and pyrrolidine dithiocarbamate of the UVB-induced cytokine expression by kertinocytes. Cytokine. 18(3):168-177. 75. Kim T, Davis J, Zhang AJ, He X, Mathews ST. 2009 Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells. Biochem Biophys Res Commun. 388(2):377-382. 76. Towler MC, Hardie DG. 2007 AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 100(3):328-341. 77. Green CJ, Macrae K, Fogarty S, Hardie DG, Sakamoto K, Hundal HS. 2011 Counter-modulation of fatty acid-induced pro-inflammatory nuclear factor κB signalling in rat skeletal muscle cells by AMP-activated protein kinase. Biochem J. 435, 463–474. 78. Lemieux K, Konrad D, Klip A, Marette A. 2003 The AMP-activatied protein kinase activator AICAR does not induce GLUT4 translocation to transverse tubules but stimulates glucose uptake and p38 mitogen-activated protein kinases alpha and beta in skeletal muscle. FASEB J. 17(12):1658-1665. 79. Somwar R, Koterski S, Sweeney G, Sciotti R, Djuric S, Berg C, Trevillyan J, Scherer PE, Rondinone CM, Klip A. 2002 A dominant-negative p38 MAPK mutant and novel selective inhibitors of p38 MAPK reduce insulin-stimulated glucose uptake in 3T3L1 adipocytes without affecting GLUT4 translocation. J Biol Chem 277(52):50386-50395. 80. Somwar R, Perreault M, Kapur S, Taha C, Sweeney G, Ramlal T, Kim DY, Keen J, Cote CH, Klip A, Marette A. 2000 Activation of p38 mitogen-activated protein kinase a and b by insulin and contraction in rat skeletal muscle: potential role in the stimulation of glucose transport. Diabetes 49(11):1794-1800. 81. Schmitz-Peiffer C, Whitehead JP. 2003 IRS-1 Regulation in Health and Disease. IUBMB Life. 55(7): 367–374. 82.Turpin SM, Lancaster GI, Darby I, Febbraio MA, Watt MJ. 2006 Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulin resistance. Am J Physiol Endocrinol Metab. 291(6):E1341-E1350. 83. Rachek LI, Musiyenko SI, LeDoux SP, Wilson GL. 2007 Palmitate induced mitochondrial deoxyribonucleic acid damage and apoptosis in l6 rat skeletal muscle cells. Endocrinology. 148(1):293-299. 84. McGarry JD. 1992 What if Minkowski had been ageusic? An alternative angle on diabetes. Science. 258(5083):766-770. 85. Dong Z. 2000 Effects of food factors on signal transduction pathways. Biofactors. 12(1-4):17-28. 86. Anton S, Melville L, Rena G. 2007 Epigallocatechin gallate (EGCG) mimics insulin action on the transcription factor FOXO1a and elicits cellular responses in the presence and absence of insulin. Cell Signal. 19(2):378-383. 87. Hale PJ, Horrocks PM, Wright AD, Fitzgerald MG, Nattrass M, Bailey CJ. 1989 Xiaoke tea, a Chinese herbal treatment for diabetes mellitus. Diabet Med. 6(8):675-676. 88. Way TD, Lin HY, Kuo DH, Tsai SJ, Shieh JC, Wu JC, Lee MR, Lin JK. 2009 Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells. J Agric Food Chem. 57(12):5257-5264. 89. Itotawa H, Shi Q, Akiyama T, Morris-Natschke SL, Lee KH. 2008 Recent advances in the investigation of curcuminoids. Chin Med. 3:11. 90. Xie W, Du L. 2011 Diabetes is an inflammatory disease: evidence from traditional Chinese medicines. Diabetes Obes Metab. 13(4):289-301. 91. De Fea K, Roth RA. 1997 Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. Biochemistry. 36(42):12939-12947. 92. Czech MP. 2002 Fat targets for insulin signaling. Mol Cell. 9(4):695-696. 93. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. 1995 High concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia. 38(10):1213-1217. 94. Conejo R, Lorenzo M. 2001 Insulin signaling leading to proliferation, survival, and membrane ruffling in C2C12 myoblasts. J Cell Physiol. 187(1):96-108. 95. Bollag GE, Roth RA, Beaudoin J, Mochly-Rosen D, Koshland DE Jr. 1986 Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Proc Natl Acad Sci U S A. 83(16):5822-5824. 96. Lam TK, Yoshii H, Haber CA, Bogdanovic E, Lam L, Fantus IG, Giacca A. 2002 Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab. 283(4):E682-E691. 97. Haasch D, Berg C, Clampit JE, Pederson T, Frost L, Kroeger P, Rondinone CM. 2006 PKCtheta is a key player in the development of insulin resistance. Biochem Biophys Res Commun. 343(2):361-368. 98. Kao YH, Chang HH, Lee MJ, Chen CL. 2006 Tea, obesity, and diabetes. Mol Nutr Food Res. 50(2):188-210. 99. Thielecke F, Boschmann M. 2009 The potential role of green tea catechins in the prevention of the metabolic syndrome - a review. Phytochemistry. 70(1):11-24. 100. Kajiya K, Kumazawa S, Nakayama T. 2001 Steric effects on interaction of tea catechins with lipid bilayers. Biosci Biotechnol Biochem. 65(12):2638-2643. 101. Kajiya K, Kumazawa S, Nakayama T. 2002 Effects of external factors on the interaction of tea catechins with lipid bilayers. Biosci Biotechnol Biochem. 66(11):2330-2335. 102. Uekusa Y, Takeshita Y, Ishii T, Nakayama T. 2008 Partition coefficients of polyphenols for phosphatidylcholine investigated by HPLC with an immobilized artificial membrane column. Biosci Biotechnol Biochem. 72(12):3289-3292. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31474 | - |
dc.description.abstract | 在過去已被報導胞漿中游離脂肪酸的提高與肌肉中所發展出的胰島素抗性有很大的相關性,並且也在肥胖及第二型糖尿病所發展出的胰島素抗性中扮演相當重要的角色。肌肉細胞中的胰島素受體基質-1 (Insulin receptor substrate-1, IRS-1) 被認為是游離脂肪酸作用的目標之一,許多研究已推斷高濃度的游離脂肪酸會活化一些絲胺酸/蘇胺酸激酶,包含蛋白質激酶C (protein kinase C, PKC)、c-jun 胺基端激酶 (c-jun N-terminal kinase, JNK) 及I kappaB激酶 (I kappaB kinase, IKK) 去增加胰島素受體基質-1絲胺酸307位置上的磷酸化,此為胰島素抗性中的一個重要特徵,經由此磷酸化修飾,會導致IRS-1上酪胺酸磷酸化下降,從而降低了其對磷脂酰肌醇3-激酶(phosphatidylinositol-3 kinase, PI3K) 的結合親和力,最後造成葡萄糖運送受到抑制。
表没食子兒茶素没食子酸酯 (epigallocatechin gallate, EGCG) 以及薑黃素 (curcumin) 兩種分別由綠茶及薑黃中萃取出來之植物多酚在過去已被推測具有抗糖尿病及抗肥胖的潛力。兩者皆可防止不正常的葡萄糖代謝,並且藉由去抑制一些細胞周期相關的激酶,包含細胞外信號調節激酶 (extracellular signal-regulated kinase 1/2, ERK1/2) 及p38有絲分裂活化蛋白質 (p38 mitogen activated protein kinase, p38 MAPK) 進而抑制脂肪細胞的增生。此外也可藉由活化 AMP-活化蛋白激酶 (AMP-activated protein kinase, AMPK) 路徑去促進能量的恆定調節。而表兒茶素没食子酸酯 (epicatechin gallate, ECG) 為另一種茶多酚,做過去已被報導其抗氧化及抗發炎的功效與EGCG相當,故推斷其可能具有抗糖尿病的效果。 骨骼肌為由胰島素促進葡萄糖吸收的主要場所,並且參與在能量的恆定調節中,因此,骨骼肌在由游離脂肪酸所引起之胰島素抗性中扮演重要的角色。在過去的報導中指出EGCG及curcumin具有改善肝臟細胞、脂肪細胞及胰臟細胞中胰島素抗性的情形,故肌肉細胞會是相當好的研究對象。 在本篇研究中我們使用了一種PKC的促效劑12-O-十四烷酰佛波醇-13-醋酸酯(12-O-tetradecanoylphorbol 13-acetate, TPA) 以及棕櫚酸去引起C2C12小鼠骨骼肌細胞中的胰島素抗性。實驗結果顯示EGCG及curcumin皆可抑制由TPA所引起之 IRS-1上的絲胺酸307位置上的磷酸化,並且促進Akt的磷酸化。此外我們發現在經過5小時棕櫚酸的培養之下,ECG可以去顯著的提高Akt, ERK1/2, p38 MAPK 以及 AMPK的活化。然而在長時間棕櫚酸的培養之下,IRS-1蛋白表現量明顯降低,但在經由EGCE, ECG 及 curcumin的處理之下可防止其被降解,並且促進Akt, MAPK路徑的活化,改善葡萄糖在肌肉細胞中吸收的情形,特別是curcumin及ECG。此外此三者多酚類亦可抑制乙醯輔酶A羧化酶 (acetyl-CoA carboxylase, ACC),但僅EGCG可顯著抑制細胞內脂肪的堆積。最後,本篇研究推測相較於其他兩者,curcumin對於改善由游離脂肪酸所引起之胰島素抗性具有最好的效果,而ECG則較EGCG來的好。 | zh_TW |
dc.description.abstract | It was reported that increased plasma levels of free fatty acids (FFA) is associated with profound insulin resistance in skeletal muscle and may also play a critical role in the insulin resistance of obesity and type 2 diabetes mellitus. Insulin receptor substrate (IRS), such as IRS-1, has been suggested as a molecular target of FFA. Various studies implicated that high level of FFA activates many serine/ threonine kinases, including PKC, JNK and IKK, and increases IRS-1 serine phosphorylation especially on 307 residue, a possible hallmark of insulin resistance in insulin- responsive cells or tissues. Such modification on IRS-1 leading to decrease IRS-1 tyrosine phosphorylation and PI3K binding affinity results in the stppression of insulin-stimulated glucose transport activity.
EGCG and curcumin, phytopolyphenol compounds derived from green tea and spice turmeric, respectively, have been suggested that they have potential of anti-diabetes and anti-obesity. Both of them prevent abnormal changes in glucose metabolism and induce a decrease phosphorylation on ERK1/2 and p-38 MAPK, two cell cycle control kinases, inhibiting adipocyte proliferation. Besides, which can also activate AMPK cascade promote energy homeostasis. ECG, another tea polyphenol, has been recently reported that was as effective as EGCG on anti-oxidation and anti-inflammation, but the potential of anti-diabetes is unknown. Skeletal muscle is the major site for insulin-stimulated glucose uptake and involved in energy regulation and homeostasis. Therefore, skeletal muscle plays an important role in FFA-induced insulin resistance. In present studies, EGCG and curcumin have display an improvement on insulin resistance in hepatocyte, adipocyte and pancreatic beta cells. Therefore, skeletal muscle cell will be a good model for investigation. In this study, we used TPA, a PKC activator, and palmitate to induce insulin resistance in C2C12 mouse skeletal muscle cells. Our data show that EGCG and curcumine treatment reduce IRS-1 Ser307 phosphorylation, and curcumine have more potent to increase Akt phosphorylation in TPA induction. Moreover, we found that after 5-h palmitate incubation, ECG can suppress IRS-1 Ser307 phosphorylation, and significantly promote Akt, ERK1/2, p38 MAPK and AMPK activation. With a longer incubation, IRS-1 exhibited a dramatically depletion, and treatment with EGCE, ECG and curcumin can reverse IRS-1 expression, Akt phosphorylation and MAPK signaling cascade activation, improving glucose uptake in C2C12 skeletal muscle cells, especially ECG and curcumin. Besides, treatment with these polyphenols can suppress ACC activation, but only EGCG could inhibit lipid accumulation in intracellular site. These findings may suggest that curcumin show the best capacity to improve FFA-induced insulin resistance than the other two, and ECG was more effective than EGCG in against insulin resistance. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T03:13:29Z (GMT). No. of bitstreams: 1 ntu-100-R98442032-1.pdf: 1970329 bytes, checksum: 44b63bb88e26bb54c1203decbaf8a3d2 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 誌謝....................................................i
中文摘要..............................................iii Abstract................................................v Table of Contents.....................................vii List of Figures........................................ix Abbreviations...........................................x Introduction............................................1 1. Insulin system and insulin action..................1 2. Insulin resistance.................................2 2.1 Insulin resistance related disease.............2 2.2 Diabetes mellitus..............................2 2.3 Obesity and insulin resistance.................3 2.4 Fatty acid induced insulin resistance in skeletal muscle.........................................4 2.5 Serine phosphorylation of IRS-1 induced by NEFA...4 3. The role of AMPK in insulin signaling and anti-obesity..........................................7 3.1 AMPK stimulated glucose uptake in muscle..........8 3.2 Regulation of fatty acid oxidation by AMPK........9 4. Tea polyphenols and curcumin.........................10 5. Specific aim...........................................11 Materials and Methods.....................................12 Results ..................................................17 Discussion................................................25 References................................................31 Figures...................................................47 Appendices................................................64 | |
dc.language.iso | en | |
dc.title | 植多酚作用於小鼠C2C12骨骼肌細胞中抑制由游離脂肪酸所引起之胰島素抗性機制探討 | zh_TW |
dc.title | Suppression of free fatty acid induced insulin resistance by phytopolyphenols in C2C12 mouse skeletal muscle cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林榮耀(Jung-Yaw Lin),蕭水銀(Shoei-Yn Shiau),徐麗芬(Lie-Fen Shyur),李宣佑(Shuan-Yow Li) | |
dc.subject.keyword | 植多酚,胰島素抗性, | zh_TW |
dc.subject.keyword | phytopolyphenol,insulin resistance, | en |
dc.relation.page | 65 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-01 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.92 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。